Clinical guides for atypical hemolytic uremic syndrome in Japan-Reference-Cited by-同舟云学术

Clinical guides for atypical hemolytic uremic syndrome in Japan

Published:2016-07 Issue:7 Volume:58 Page:549-555
ISSN:1328-8067
Container-title:Pediatrics International
language:en
Short-container-title:Pediatrics International

Author:

Kato Hideki¹,Nangaku Masaomi¹,Hataya Hiroshi²,Sawai Toshihiro³,Ashida Akira⁴,Fujimaru Rika⁵,Hidaka Yoshihiko⁶,Kaname Shinya⁷,Maruyama Shoichi⁸,Yasuda Takashi⁹,Yoshida Yoko¹,Ito Shuichi¹⁰,Hattori Motoshi¹¹,Miyakawa Yoshitaka¹²,Fujimura Yoshihiro¹³,Okada Hirokazu¹⁴,Kagami Shoji¹⁵,

Affiliation:

1. Division of Nephrology and Endocrinology; The University of Tokyo Graduate School of Medicine; Tokyo Japan

2. Department of Nephrology; Tokyo Metropolitan Children's Medical Center; Fuchu Tokyo Japan

3. Department of Pediatrics; Shiga University of Medical Science; Otsu Shiga Japan

4. Department of Pediatrics; Osaka Medical College; Takatsuki Osaka Japan

5. Department of Pediatrics; Osaka City General Hospital; Miyakojima Osaka Japan

6. Department of Pediatrics; Shinshu University School of Medicine; Matsumoto Nagano Japan

7. First Department of Internal Medicine; Kyorin University School of Medicine; Mitaka Tokyo Japan

8. Department of Nephrology; Nagoya University Graduate School of Medicine; Nagoya Aichi Japan

9. Kichijoji Asahi Hospital; Musashino Tokyo Japan

10. Department of Pediatrics; Graduate School of Medicine; Yokohama City University; Kanazawa Yokohama Japan

11. Department of Pediatric Nephrology; Tokyo Women's Medical University; Shinjuku Tokyo Japan

12. Department of General Internal Medicine; Faculty of Medicine; Saitama Medical University; Iruma Saitama Japan

13. Department of Blood Transfusion Medicine; Nara Medical University; Kashihara Nara Japan

14. Department of Nephrology; Faculty of Medicine; Saitama Medical University; Iruma Saitama Japan

15. Department of Pediatrics; Graduate School of Medical Sciences; Tokushima University; Tokushima Japan

Funder

Ministry of Health, Labour and Welfare Grants-in-Aid Program

Daiichi Sankyo Co., Ltd.

Astellas Pharma Inc.

AstraZeneca K.K.

Alexion Pharmaceuticals, Inc.

GlaxoSmithKline K.K.

Taisho Pharmaceutical Co., Ltd.

Mitsubishi Tanabe Pharma Corp.

Japan Tobacco Inc.

Bayer Yakuhin, Ltd.

Otsuka Pharmaceutical Co., Ltd

Medical Review Co., Ltd.

Seishokai Medical Corporation

Keyaki-Kai Medical Corporation

Sumitomo Dainippon Pharma Co., Ltd.

Mochida Pharmaceutical Co., Ltd.

Nippon Boehringer Ingelheim Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

Torii Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Company

Novartis Pharma K.K.

Pfizer Japan Inc.

MSD K.K.

Kyowa Hakko Kirin Co., Ltd.

Publisher

Wiley

Subject

Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ped.13044/fullpdf

Reference44 articles.

1. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin;Thompson;Clin. Exp. Immunol.,1981

2. Genetic studies into inherited and sporadic hemolytic uremic syndrome;Warwicker;Kidney Int.,1998

3. Factor H gene variants in Japanese: its relation to atypical hemolytic uremic syndrome;Mukai;Mol. Immunol.,2011

4. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society;Sawai;Clin. Exp. Nephrol.,2014

5. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society;Sawai;Pediatr. Int.,2014

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. My serendipity —Treasure every encounter—;Japanese journal of pediatric nephrology;2024

2. Clinical features of women with thrombotic microangiopathy in pregnancy: A case series from a single Japanese tertiary perinatal care center;Journal of Obstetrics and Gynaecology Research;2023-09-06

3. Immune responses and safety of COVID-19 vaccination in atypical hemolytic uremic syndrome patients in Taiwan;Vaccine;2023-09

4. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan;International Journal of Hematology;2023-07-29

5. Application of a scoring system in Japanese patients diagnosed with atypical hemolytic uremic syndrome to assess the relationship between the score and clinical responses to eculizumab;Thrombosis Journal;2023-04-18